https://africadailyjournal.com/article/904984928-applications-open-for-dnda26-awards-celebrating-humanity-centered-design-for-societal-impact-and-global-well-being Africa Daily Journal en PressRelease 2026-04-13T11:00:00+00:00 Applications Open for DNDA26 Awards: Celebrating Humanity-Centered Design for Societal Impact and Global Well-Being https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24830562-dnda25-laureates-3240x2160.jpeg https://africadailyjournal.com/article/905446990-outsourced-cfo-to-participate-in-african-incubator-value-creation-series Africa Daily Journal en PressRelease 2026-04-13T08:43:22+00:00 Outsourced CFO to Participate in African Incubator Value Creation Series https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24831147-group-of-people-standing-around-1500x1000.jpeg https://africadailyjournal.com/article/905415185-ai-workforce-enablement-emerges-as-a-strategic-imperative-in-the-enterprise-ai-era Africa Daily Journal en PressRelease 2026-04-13T05:44:51+00:00 AI Workforce Enablement Emerges as a Strategic Imperative in the Enterprise AI Era https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24831008-ai-workforce-enablement-image-1000x600.jpeg https://africadailyjournal.com/article/904680737-fmuser-announces-hardware-based-iptv-system-for-isps-in-the-middle-east-and-africa Africa Daily Journal en PressRelease 2026-04-13T05:32:29+00:00 FMUSER Announces Hardware-Based IPTV System for ISPs in the Middle East and Africa https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24830707-1-1920x1080.png https://africadailyjournal.com/article/905478602-optum-united-healthcare-united-behavioral-health-expands-neurostar-tms-coverage-to-include-psychiatric-mental-health-nurse-practitioners Africa Daily Journal en PressRelease 2026-04-13T12:32:00+00:00 Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners https://ml.globenewswire.com/media/12db9039-d4bf-41a0-8b4a-324398e392b4/small/neuronetics-logo-rgb-purple-png.png https://africadailyjournal.com/article/905478464-alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer Africa Daily Journal en PressRelease 2026-04-13T12:30:00+00:00 ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer https://ml.globenewswire.com/media/0a1b4459-3df3-4c9f-ba29-ace8d7ad1b9a/small/alx-01-stacked-white-png.png https://africadailyjournal.com/article/905474988-septerna-announces-initiation-of-phase-1-clinical-trial-of-sep-479-an-oral-small-molecule-pth1r-agonist-for-the-treatment-of-hypoparathyroidism Africa Daily Journal en PressRelease 2026-04-13T12:00:00+00:00 Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism https://ml.globenewswire.com/media/8c635733-2794-456f-9bc4-3b53908acba9/small/septernalogo-black-10x-jpg.jpg https://africadailyjournal.com/article/905474993-global-uranium-corp-announces-completion-of-geological-mapping-at-the-airline-project-in-wyoming Africa Daily Journal en PressRelease 2026-04-13T12:00:00+00:00 Global Uranium Corp. Announces Completion of Geological Mapping at the Airline Project in Wyoming https://ml.globenewswire.com/media/ee2655b6-8532-431c-8045-cc4c311681ae/medium/figure-1.jpg https://africadailyjournal.com/article/905475004-favorable-results-of-ovarian-cancer-study-presented-at-annual-society-of-gynecological-care-conference Africa Daily Journal en PressRelease 2026-04-13T12:00:00+00:00 Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference https://ml.globenewswire.com/media/7e828ef4-6c8f-4c94-b376-4e3749530fba/small/logo-jpg.jpg https://africadailyjournal.com/article/905475009-praxis-to-showcase-essential3-the-first-positive-phase-3-program-in-essential-tremor-at-aan-2026 Africa Daily Journal en PressRelease 2026-04-13T12:00:00+00:00 Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://africadailyjournal.com/article/905475045-daraxonrasib-demonstrates-unprecedented-overall-survival-benefit-in-pivotal-phase-3-rasolute-302-clinical-trial-in-patients-with-metastatic-pancreatic Africa Daily Journal en PressRelease 2026-04-13T12:00:00+00:00 Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://africadailyjournal.com/article/905474987-nervgen-pharma-to-participate-in-the-h-c-wainwright-hcw-home-series-and-the-2026-bloom-burton-co-healthcare-investor-conference Africa Daily Journal en PressRelease 2026-04-13T11:45:00+00:00 NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference https://ml.globenewswire.com/media/bb42d0ef-06b6-4b90-8389-ca991092aa37/small/nervgen-logo-updated-globenewswire-png.png https://africadailyjournal.com/article/905470696-deep-sea-minerals-corp-appoints-dan-mcconnell-as-vice-president-of-exploration Africa Daily Journal en PressRelease 2026-04-13T11:30:00+00:00 DEEP SEA MINERALS CORP. APPOINTS DAN MCCONNELL AS VICE PRESIDENT OF EXPLORATION https://ml.globenewswire.com/media/811181eb-f1f6-4baf-9d4e-783d1d472b55/small/deep-sea-logo-jan2026-jpg-png.png https://africadailyjournal.com/article/905470717-allogene-therapeutics-reports-interim-futility-analysis-from-pivotal-alpha3-trial-showing-58-3-mrd-clearance-with-cemacabtagene-ansegedleucel Africa Daily Journal en PressRelease 2026-04-13T11:30:00+00:00 Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL https://ml.globenewswire.com/media/87e8712c-0741-409f-9942-c91b31e7c5e1/small/allogene-png.png https://africadailyjournal.com/article/905470743-fredonia-mining-inc-grants-stock-options-and-formalizes-management-agreements Africa Daily Journal en PressRelease 2026-04-13T11:30:00+00:00 Fredonia Mining Inc. Grants Stock Options and Formalizes Management Agreements https://ml.globenewswire.com/media/a2c40d42-717c-4ff9-9856-afe582a0f392/small/fredonia-logo-jpg.jpg https://africadailyjournal.com/article/905470793-gelatide-drops-investigated-2026-report-what-consumers-should-verify-before-buying Africa Daily Journal en PressRelease 2026-04-13T11:23:50+00:00 Gelatide Drops Investigated (2026 Report) What Consumers Should Verify Before Buying https://ml.globenewswire.com/Resource/Download/984a2986-fdd3-4fe6-80f2-312f9d1cbc94/image2.png https://africadailyjournal.com/article/905466795-eclipse-life-sciences-completes-enrollment-in-phase-2-study-evaluating-ec-104-for-diabetic-macular-edema-dme Africa Daily Journal en PressRelease 2026-04-13T11:00:00+00:00 Eclipse Life Sciences Completes Enrollment in Phase 2 Study Evaluating EC-104 for Diabetic Macular Edema (DME) https://ml.globenewswire.com/media/3ed9dd28-ed00-4f7d-b5b9-1180c2c99262/small/eclipse-logo-png.png https://africadailyjournal.com/article/905466986-ocular-therapeutix-announces-additional-positive-week-52-data-from-landmark-sol-1-phase-3-trial-of-axpaxli-in-wet-amd Africa Daily Journal en PressRelease 2026-04-13T11:00:00+00:00 Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://africadailyjournal.com/article/905466998-gfg-exercises-its-option-and-earns-100-in-the-6-500-hectare-wwcc-property-in-the-prolific-timmins-gold-district Africa Daily Journal en PressRelease 2026-04-13T10:50:00+00:00 GFG Exercises its Option and Earns 100% in the 6,500-Hectare WWCC Property in the Prolific Timmins Gold District https://ml.globenewswire.com/media/b9b9e049-6bf9-4789-bd45-659aff312d7b/medium/figure-1-regional-map-of-gfg-gold-projects-in-the-timmins-go.jpg https://africadailyjournal.com/article/905467025-leanzene-gummies-examined-2026-consumer-focused-breakdown-of-ingredients-claims-label-transparency Africa Daily Journal en PressRelease 2026-04-13T10:47:40+00:00 Leanzene Gummies Examined: 2026 Consumer-Focused Breakdown of Ingredients, Claims & Label Transparency https://ml.globenewswire.com/Resource/Download/e7b8402e-d943-467a-8865-1fec7f5629cc/image2.png https://africadailyjournal.com/article/905463067-a-i-s-resources-engages-geo-data-solutions-gds-inc-to-complete-a-high-resolution-helicopter-borne-magnetic-survey-to-support-exploration-across-its Africa Daily Journal en PressRelease 2026-04-13T10:30:00+00:00 A.I.S. Resources engages Geo Data Solutions GDS Inc. to complete a high-resolution helicopter-borne magnetic survey to support exploration across its St. John Project https://ml.globenewswire.com/media/66594a75-4949-430b-9954-d9e7e29a5778/small/aislogo-png.png https://africadailyjournal.com/article/905463143-telix-and-regeneron-announce-strategic-radiopharma-collaboration Africa Daily Journal en PressRelease 2026-04-13T10:30:00+00:00 Telix and Regeneron Announce Strategic Radiopharma Collaboration https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png https://africadailyjournal.com/article/905459678-mexc-doubles-market-share-to-9-in-two-years-coingecko-reports Africa Daily Journal en PressRelease 2026-04-13T10:00:00+00:00 MEXC Doubles Market Share to 9% in Two Years, CoinGecko Reports https://ml.globenewswire.com/media/e03bb1f5-f602-49a7-8ab8-5ffdea5088da/medium/mexc-doubles-market-share-to-9-in-two-years-coingecko-report.png https://africadailyjournal.com/article/905385512-nxera-pharma-s-partner-neurocrine-biosciences-doses-first-patient-in-phase-2-trial-of-nbi-1117570-for-adults-with-schizophrenia Africa Daily Journal en PressRelease 2026-04-12T23:30:00+00:00 Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia https://ml-eu.globenewswire.com/media/5cc74d52-c86f-4e21-8684-3496281fee15/small/nxera-master-logo-rgb-black-1-png.png